Is CELU or CMMB more undervalued in 2026?

CirclFi compares Celularity Inc. (CELU) and Chemomab Therapeutics Ltd. (CMMB) using 13 institutional-grade valuation models. CELU has a Quality of Company score of 4.9/10 while CMMB scores 1.9/10.

Which is a better buy — CELU or CMMB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CELU and CMMB valuations compare?

CELU at $1.01 and CMMB at $2.00 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CELU vs CMMB Valuation Comparison 2026 — Intrinsic Value Analysis

CELU

Pharmaceutical Preparations

Celularity Inc.

Quality

4.9

out of 10

Value Trap

LOW

Price

$1.01

Last close

Models

7/13

Active

CMMB

Pharmaceutical Preparations

Chemomab Therapeutics Ltd.

Quality

1.9

out of 10

Value Trap

SAFE

Price

$2.00

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	CELU Fair Value	CELU Upside	CMMB Fair Value	CMMB Upside
Bayesian DCF	Intrinsic	—	—	$0.44	-77.9%
Earnings Power Value	Intrinsic	$3.41	+256.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$3.98	+293.9%	—	—
Regime Cross-Sectional	Relative	$0.01	-99.0%	$0.10	-94.9%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CELU vs CMMB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CELU vs CMMB — Which Stock Is More Undervalued?

CELU scores higher with a 4.9/10 quality rating vs CMMB's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Celularity Inc. (CELU) and Chemomab Therapeutics Ltd. (CMMB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CELU currently trades at $1.01 with a QOC of 4.9/10, while CMMB trades at $2.00 with a QOC of 1.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).